lifestyle.smarttalksuccess.com

Author: BriaCell Therapeutics Corp.

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

May 5, 2026
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

May 4, 2026
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

May 4, 2026
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

May 2, 2026
BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

April 30, 2026
BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

April 29, 2026
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

April 28, 2026
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

February 18, 2026
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

February 17, 2026
BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

January 28, 2026